E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS
Koji Sasaki,Elias Jabbour,Guillermo Montalban-Bravo,Faezeh Darbaniyan,Kim Anh Do,Caleb A. Class,Nicholas J. Short,Rashmi Kanagal-Shamana,Tapan M. Kadia,Gautam Borthakur,Naveen Pemmaraju,Jorge E. Cortes,Farhad Ravandi,Yesid Alvarado,Kelly S. Chien,Rami Komrojki,Mikkael A. Sekeres,David P. Steensma,Amy E. DeZern,Gail J. Roboz,Kelly A. Soltysiak,Huiying Yang,Hagop M. Kantarjian,Guillermo Garcia-Manero +23 more
TL;DR: In this paper , the authors used the International Probabilistic Scoring System (IPS) with a Bayesian response-adaptive design to assign patients with low/intermediate-1 risk to receive either 20 mg/m2 decitabine daily or 75 mg /m2 azacitidine daily on days 1 to 3 every 28-day cycle.
Journal ArticleDOI
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy
Nicholas J. Short,Christopher B. Benton,Hsiang Chun Chen,Peng Qiu,Lisa Gu,Sherry Pierce,Mark Brandt,Abhishek Maiti,Taejin L. Min,Kiran Naqvi,Alfonso Quintás-Cardama,Marina Konopleva,Tapan M. Kadia,Jorge E. Cortes,Guillermo Garcia-Manero,Farhad Ravandi,Elias Jabbour,Hagop M. Kantarjian,Michael Andreeff +18 more
TL;DR: A retrospective analysis of 363 patients with untreated AML who received induction chemotherapy to determine the relationship between day of blast disappearance (DOBD) and complete remission (CR) rates, event‐free survival (EFS) and overall survival (OS).
Journal ArticleDOI
Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report.
Sebastian Burgos,Guillermo Montalban-Bravo,Lucia Fuente,Elias Jabbour,Rashmi Kanagal-Shamanna,Kelly A. Soltysiak,Guillermo Garcia-Manero,Maria J. Mela-Osorio +7 more
TL;DR: This case highlights the importance of NGS as a diagnostic and surveillance tool for MDS and shows an extremely rare progression of del(5)(q22q35) MDS to B-ALL with accompanying NGS data and a newly described acquisition of an EZH2 frameshift mutation.
Journal ArticleDOI
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis
Mahran Shoukier,Gautam Borthakur,Elias Jabbour,Farhad Ravandi,Guillermo Garcia-Manero,Tapan M. Kadia,Jairo Matthews,Lucia Masarova,Kiran Naqvi,Koji Sasaki,Srdan Verstovsek,Jorge E. Cortes +11 more
TL;DR: Eltrombopag may help improve platelet counts in CML patients receiving TKI with recurrent thrombocytopenia and further studies are warranted.
Journal ArticleDOI
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
Shunsuke Kimura,Lindsey E. Montefiori,Ilaria Iacobucci,Yaqi Zhao,Qingsong Gao,Elisabeth Paietta,Claudia Haferlach,A. Douglas Laird,Paul E. Mead,Zhaohui Xu,Wendy Stock,Mark R. Litzow,Jacob M. Rowe,Selina M. Luger,Stephen P. Hunger,Georgina L Ryland,Breon Schmidt,Paul G Ekert,Alicia Oshlack,Sean M. Grimmond,Jacqueline Rehn,James Breen,David T Yeung,Deborah L. White,Ibrahim Aldoss,Elias Jabbour,Ching-Hon Pui,Manja Meggendorfer,Wencke Walter,Wolfgang Kern,Torsten Haferlach,Samuel W. Brady,Jinghui Zhang,Kathryn G. Roberts,Piers Blombery,Charles G. Mullighan +35 more
TL;DR: